Glenmark Pharma: Is the rally in the stock sustainable?
Asset monetisation, plant clearance, and earnings growth baked into estimates and valuations19-08-2023
19-08-2023
Glenmark Pharma gets USFDA nod for Tacrolimus Ointment; stock trades lower
The company had reported an 18 percent decline in consolidated net profit at Rs 173.13 crore in the first quarter ended June 30, 2023.17-08-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%17-08-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q1 FY 2023-24 Earnings Call held on 14th August, 2023 on the website of the Company.14-08-2023
Q1FY24 Quarterly Result Announced for Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals announced Q1FY24 results: Europe Business grew by 73.7% to Rs 5,732 million. ROW Business grew by 30.4% to Rs 5,512 million. North America Business grew by 22% to Rs 8,085 million. India's Business grew by 2.8% to Rs 10,643 million. EBITDA of Rs 6,312 million grew by 46.2% YoY, with margins of 18.6%. Consolidated revenue was at Rs 34,016 million as against Rs 27,773 million recording an increase of 22.5% YoY. Profit After Tax (PAT) for Q1FY24 was at Rs 1,731 million. “We had yet another strong quarter both in terms of revenue and operating margins. The robust growth in sales was led by our branded markets in the RoW region. Our Europe business performed significantly well on the back of a strong generics portfolio and continued gains in market share, in our leading respiratory brands. Our North American business remained stable, and our India business continued to significantly outperform industry growth rates. We also had our GHG emission targets certified by the Science Based Targets initiative (SBTi) giving us an impetus to further pursue our ESG goals, while also benchmarking us at a global scale.” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals. He further added, “Going forward our goal remains to sustain the momentum, as RYALTRIS continues to meaningfully contribute across all the covered markets. We also remain on track to achieve our objectives for FY24.” Result PDF14-08-2023
Glenmark Pharmaceuticals Results Earnings Call for Q1FY24
Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.14-08-2023
Glenmark Pharma Q1 Results: Net profit falls 18% to 173.13 cr, revenue up 22%
The company had posted a consolidated net profit of 211.1 crore in the same quarter last fiscal, Glenmark Pharmaceuticals said in a regulatory filing.14-08-2023
Glenmark Pharma Q1 net profit falls 18% to Rs 173.13 crore
Sales from the formulation business in India in Q1 was at Rs 1,064.3 crore over Rs 1,035.2 crore in the previous corresponding quarter, a growth of 2.8 per cent, the company said, adding, in North America, sales of finished dosage formulations clocked Rs 808.5 crore as against Rs 662.8 crore in the same period a year ago.11-08-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Change in Senior Management11-08-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation - Q1 FY 23-2411-08-2023